Search results
Added:
1 month ago
AHA Scientific Sessions 2025 - Dr Nils Krüger (Brigham and Women's Hospital, US) joins us to discuss findings from the TIRZSEMA-CVOT (NCT07096063) study, examining real-world cardiovascular outcomes with tirzepatide and semaglutide in patients with type 2 diabetes at cardiovascular risk.This retrospective cohort study utilized three national US claims databases to evaluate over 887,000 patients…
View more
e-SPACE HF 2024 – Day Two
Start date:
Oct 19, 2024
Broadcast
e-SPACE HF 2024 – Day One
Start date:
Oct 18, 2024
Broadcast
Start date:
Jul 02, 2025
.img-row:after {
content: "";
clear: both;
display: table;
}
.img-column {
float: left;
width: 50%;
padding: 5px;
}
@media screen and (max-width: 500px) {
.img-column {
width: 100%;
}
}
Join James Burton (University of Leicester, Leicester, UK), Clara Bonanad (University Clinical Hospital of Valencia, Valencia, ES), Aaron Wong (Princess of Wales Hospital, Bridgend, Wales, UK)…
View more
e-SPACE CRM 2024 - Day 2
Start date:
Mar 23, 2024
Broadcast
e-SPACE CRM 2024 - Day 1
Start date:
Mar 22, 2024
Broadcast
Added:
3 months ago
Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcenter, Erasmus MC, Rotterdam, NL) discuss the most anticipated hot line studies to be unveiled at ESC Congress 2025. Tune in for their in-depth analysis to get ahead of the curve.ESC Congress 2025 Hot Line Trials Discussed:VICTORVICTORIADIGIT-HFDAPA-ACT-HF-TIMIREBOOT-CNICBETAMI-DANBLOCKREFINE ICDStay tuned for Radcliffe Cardiology’s in-depth…
View more
Rossana Bussani
Author
Added:
1 month ago
AHA Scientific Sessions 2025 - Dr Milton Packer (Baylor University Medical Center, US) joins us to discuss his novel unifying hypothesis that heart failure with preserved ejection fraction arises primarily from visceral adipose tissue dysfunction and altered adipokine signaling, rather than as a heterogeneous disorder driven by multiple comorbidities.Interview Questions:Can you explain the core…
View more
Added:
1 month ago
AHA Scientific Sessions 2025 – Late-breaker host Dr Harriette Van Spall (McMaster University, CA) is joined by Prof Stephen Nicholls (Monash University, AU) to present the findings of this AHA late-breaking trial.This pre-specified analysis of the SURPASS-CVOT randomised clinical trial evaluates the comparative effects of once-weekly tirzepatide versus dulaglutide on heart failure outcomes in…
View more